Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
CagriSema: Evidence Summary
Evidence summary for CagriSema across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to CagriSema overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Chronic weight management | Tier A | 4 | REDEFINE 1 (N=3,417): 22.7% weight loss at 68 wk; REDEFINE 2 (N=1,206): weight loss in T2D; both published NEJM June 2025 |
| Type 2 diabetes with obesity | Tier B | 2 | REDEFINE 2 showed significant weight loss and HbA1c reduction in T2D population |
| Cardiovascular risk reduction | Tier D | 1 | REDEFINE CVOT ongoing — no outcomes data yet |
References (5)
- CagriSema for obesity: REDEFINE 1 Phase 3 trial — Garvey WT et al. . New England Journal of Medicine (2025) PMID: 40544433
- CagriSema for obesity with type 2 diabetes: REDEFINE 2 Phase 3 trial — Knop FK et al. . New England Journal of Medicine (2025) PMID: 40544432
- Cagrilintide plus semaglutide in type 2 diabetes: Phase 2 trial — Drucker DJ et al. . Lancet (2023) PMID: 37364590
- Cagrilintide/semaglutide Phase 1b pharmacokinetics and pharmacodynamics — Funch D et al. . Lancet (2021) PMID: 33894838
- REDEFINE 1: Cagrilintide/semaglutide vs placebo in obesity — Novo Nordisk (2025) NCT05394519